Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit

Mycoses

Volumn 54, Issue 1, 2011, Pages 46-51

  Ostrosky Zeichner, Luis ^a   Pappas, Peter G ^b   Shoham, Shmuel ^c   Reboli, Annette ^d   Barron, Michelle A ^e   Sims, Charles ^a   Wood, Craig ^f   Sobel, Jack D ^g  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c WASHINGTON HOSPITAL CENTER   (United States)

^d RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

^g WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Candida; Intensive care unit; Prediction rule

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT;

APACHE; ARTICLE; ARTIFICIAL VENTILATION; CENTRAL VENOUS CATHETER; DIAGNOSTIC ACCURACY; HUMAN; INFECTION PREVENTION; INTENSIVE CARE UNIT; INVASIVE CANDIDIASIS; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

ANTIFUNGAL AGENTS; APACHE; CANDIDIASIS, INVASIVE; CHEMOPREVENTION; CLINICAL TRIALS AS TOPIC; CROSS INFECTION; HUMANS; INTENSIVE CARE UNITS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

CANDIDA;

EID: 78649805056     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2009.01756.x     Document Type: Article

References (17)

1. Blumberg HM, Jarvis WR, Soucie JM, et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 2001; 33: 177-86.
2. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24 179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-17.
3. Rentz AM, Halpern MT, Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 1998; 27: 781-8.
4. Gudlaugsson O, Gillespie S, Lee K, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37: 1172-7.
5. Blot SI, Vandewoude KH, Hoste EA, Colardyn FA. Effects of nosocomial candidemia on outcomes of critically ill patients. Am J Med 2002; 113: 480-5.
6. Sobel JD, Rex JH. Invasive candidiasis: turning risk into a practical prevention policy? Clin Infect Dis 2001; 33: 187-90.
7. Rex JH, Sobel JD. Prophylactic antifungal therapy in the intensive care unit. Clin Infect Dis 2001; 32: 1191-200.
8. Swoboda SM, Merz WG, Lipsetta PA. Candidemia: the impact of antifungal prophylaxis in a surgical intensive care unit. Surg Infect (Larchmt) 2003; 4: 345-54.
9. Piarroux R, Grenouillet F, Balvay P, et al. Assessment of pre-emptive treatment to prevent severe candidiasis in critically ill surgical patients. Crit Care Med 2004; 32: 2443-9.
10. Garbino J, Lew DP, Romand JA, Hugonnet S, Auckenthaler R, Pittet D. Prevention of severe candida infections in non-neutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med 2002; 28: 1708-17.
11. Pelz RK, Hendrix CW, Swoboda SM, et al. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg 2001; 233: 542-8.
12. Eggimann P, Francioli P, Bille J, et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med 1999; 27: 1066-72.
13. Ostrosky-Zeichner L, Sable C, Sobel J, et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 2007; 26: 271-6.
14. Ostrosky-Zeichner L, Sobel J, Pappas P, et al.. Pilot Study of Risk-Based Caspofungin (CFG) Prophylaxis in the ICU: Lessons from a Multicenter, Randomized, Double Blind Trial and Insights into Diagnostic Performance of Surrogate Markers. Abstract M-1158. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2007.
15. Ascioglu S, Rex JH, De Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
16. Dupont H, Bourichon A, Paugam-Burtz C, Mantz J, Desmonts JM. Can yeast isolation in peritoneal fluid be predicted in intensive care unit patients with peritonitis? Crit Care Med 2003; 31: 752-7.
17. Leon C, Ruiz-Santana S, Saavedra P, et al. A bedside scoring system ('Candida score') for early antifungal treatment in non-neutropenic critically ill patients with Candida colonization. Crit Care Med 2006; 34: 730-7.